Figure 3 The top 10 results of one-way sensitivity analyses comparing the HAIC-FO strategy to the sorafenib strategy in the overall population. The tornado diagram visually depicts the influence of varying model parameters on the incremental cost-effectiveness ratio (ICER) of the HAIC-FO strategy relative to the sorafenib strategy. The solid line intersects the bars, representing the ICER of $9,720 per quality-adjusted life year (QALY) as obtained in the base case results. HAIC-FO – hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; PFD – progression-free disease; PD – progressed disease.